Canadian Journal of Urology, Vol.32, No.2, pp. 71-72, 2025, DOI:10.32604/cju.2025.066690 - 30 April 2025

Abstract This article has no abstract. More >

Nicholas Sellke^1,2,*, Erin Jesse^1,2, Justin M. Dubin³, Tomislav D. Medved^1,2, Neha S. Basti⁴, Janvi Ramchandra², Robert E. Brannigan⁴, Joshua A. Halpern⁴, Nannan Thirumavalavan^1,2

Canadian Journal of Urology, Vol.32, No.2, pp. 89-94, 2025, DOI:10.32604/cju.2025.065004 - 30 April 2025

Abstract Introduction: Direct-to-consumer (DTC) telemedicine has emerged as an option for transgender patients seeking gender affirming hormone therapy (GAHT). We aimed to characterize the healthcare services provided by DTC telemedicine companies offering GAHT and to compare their costs to a tertiary care center. Methods: We identified DTC telemedicine platforms offering GAHT via internet searches and extracted information from their websites related to evaluation, treatment, monitoring, and cost. Cost of the DTC GAHT was compared to cost for comparable services at a tertiary care center. Results: Six DTC companies were identified. All platforms utilized an informed consent model… More >

Tatiana Henriksson^1,*, Katharina Mitchell², Reima El Naili³, Ali Hajiran²

Canadian Journal of Urology, Vol.32, No.2, pp. 95-99, 2025, DOI:10.32604/cju.2025.065002 - 30 April 2025

Abstract Renal cell carcinoma is a heterogeneous group of renal tumors characterized by several histological subtypes. Herein, we discuss an unusual case of a 55-year-old male who presented as a consultation to our urology clinic with an incidentally found renal mass. After shared decision making patient proceeded with a Robotic Assisted Laparoscopy (RAL) left sided partial nephrectomy. Final pathology confirmed the presence of high nuclear grade mixed clear cell and papillary renal cell carcinoma (RCC) of the left kidney (pT3aN0M0). This case elucidates a very rare incidence of a patient seen to have a collision tumor, More >

Peter T. Scardino

Canadian Journal of Urology, Vol.32, No.2, pp. 73-80, 2025, DOI:10.32604/cju.2025.064714 - 30 April 2025

Abstract This article has no abstract. More >

Demirhan Örsan Demir^1,*, Yusuf Gökkurt¹, Salih Bürlükkara², Turgay Kaçan¹, Ali Kaan Yıldız¹, Ufuk Bozkurt², Tolga Karakan¹

Canadian Journal of Urology, Vol.32, No.2, pp. 111-118, 2025, DOI:10.32604/cju.2025.063970 - 30 April 2025

Abstract Introduction: Surgeons typically prefer 270 µm and 272 µm laser probes in retrograde intrarenal surgery (RIRS) due to the reduced deflection capacity of flexible ureterorenoscopes when using larger probe diameters. This study aims to investigate the effects of 272 and 365 µm holmium laser probes on operative time, clinical efficacy, and complication rates in RIRS. Materials and Methods: A total of 285 patients with proximal ureteral or kidney stones who met the inclusion criteria were enrolled in the study. Patients were divided into two groups based on laser probe thickness: 272 µm and 365 µm. Stone-free… More >

Mihály Murányi^1,*, András Domoszlai¹, Attila Csaba Nagy², Tibor Flaskó¹

Canadian Journal of Urology, Vol.32, No.2, pp. 119-127, 2025, DOI:10.32604/cju.2025.063821 - 30 April 2025

Abstract Introduction: We aimed to compare the oncological and functional outcomes of glansectomy and split-thickness skin graft reconstruction (GR) with those of glansectomy alone (GA) and penile amputation (PA). Materials and Methods: This retrospective study included patients with penile carcinoma or penile intraepithelial neoplasia diagnosed between 2017 and 2022. Surgical outcomes, complications, and oncological outcomes were assessed through a chart review, and functional outcomes were assessed using a questionnaire administered to patients who underwent GR (group A), GA (group B), or PA (group C). Results: Six, eight, and seven patients were enrolled in groups A, B, and… More >

Mark Shilling¹, Lauren S. Faber², Hoi Doan², Merry Peckham², Timothy R. Petersen^1,3, Reza Ehsanian¹, Frances Alba^2,*

Canadian Journal of Urology, Vol.32, No.2, pp. 81-88, 2025, DOI:10.32604/cju.2025.063415 - 30 April 2025

Abstract Introduction: Existing literature has highlighted disparities in acute pain management across racial and sex groups in both emergency department and pre-hospital settings. This study aimed to evaluate prescribing patterns among physicians and advanced practice providers for patients with upper tract urolithiasis in an academic emergency department. Materials and Methods: Retrospective chart review of patients diagnosed with upper tract urolithiasis was performed to evaluate age, sex, race, ethnicity, stone size and location, presence of hydronephrosis, admission status, history of prior nephrolithiasis, medications administered in the emergency department (ED), requests for urology consult or referral, and discharge medications. More >

Miguel Ángel Gómez-Luque^*, Guillermo Lendínez-Cano, Carmen Belén Congregado-Ruiz, Ignacio Osman-García, Rafael Antonio Medina-López

Canadian Journal of Urology, Vol.32, No.2, pp. 101-109, 2025, DOI:10.32604/cju.2025.063073 - 30 April 2025

Abstract Introduction: In recent years, significant advancements in the treatment of metastatic renal cell carcinoma (mRCC) have notably extended overall survival (OS) times, particularly with the introduction of tyrosine kinase inhibitors (TKIs) and combination immunotherapy. However, survival outcomes in mRCC remain highly variable. Materials and Methods: This study retrospectively analyzed clinical and demographic factors at diagnosis in patients treated for mRCC to identify predictors of long-term survival (defined as OS ≥ 48 months). Patients were categorized into long-term survivors (LTS) and non-long-term survivors (nLTS). Results: The analysis revealed that factors such as better Karnofsky Performance Status (KPS), More >

Yash B. Shah¹, Courtney E. Capella^1,*, Rishabh K. Simhal², Maria J. D’Amico¹, Whitney Smith¹, Alana M. Murphy¹

Canadian Journal of Urology, Vol.32, No.1, pp. 63-70, 2025, DOI:10.32604/cju.2025.064711 - 20 March 2025

Abstract Introduction: With the aging population, more females will suffer from pelvic organ prolapse. Both urologists and gynecologists perform sacrocolpopexy, but there is no comparative study analyzing differences in provision of care, outcomes, or patient population. We aimed to elucidate potential differences in demographics, outcomes, and minimally invasive surgery utilization for SCP performed by urology and gynecology. Methods: In our retrospective analysis, sacrocolpopexies were identified using the American College of Surgeons National Surgical Quality Improvement Project database from 2006–2020. Pearson’s chi-square test was performed to test trends in the utilization of MIS in five-year blocks. Frailty… More >

Badrinath R. Konety^1,*, Yair Lotan², Amanda Myers³

Canadian Journal of Urology, Vol.32, No.1, pp. 29-36, 2025, DOI:10.32604/cju.2025.064710 - 20 March 2025

Abstract Introduction: Non–muscle-invasive bladder cancer (NMIBC) is a common malignancy worldwide. While Bacillus Calmette-Guérin (BCG) is standard of care for treatment for most patients with high-risk NMIBC, many will either not respond to BCG initially or will eventually develop BCG-unresponsive disease. A treatment option in BCG-unresponsive disease is nadofaragene firadenovec-vncg (Adstiladrin), a nonreplicating adenoviral vector–based gene therapy approved by the US Food and Drug Administration (FDA) for the treatment of adults with high-risk BCG-unresponsive NMIBC with carcinoma in situ with or without papillary tumors. Objective: To review safety outcomes of participants who received the FDA-approved dose… More >